Summary & Overview
CPT 87269: Immunofluorescent Detection of Giardia Antigen
CPT code 87269 denotes an immunofluorescent laboratory assay performed to detect Giardia antigens, a targeted parasitology diagnostic used to confirm giardiasis. This code is used nationally across clinical and hospital laboratories and matters for clinical diagnosis, infection control, and public health surveillance where timely, specific parasitic identification alters treatment and containment decisions. Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on the clinical purpose of the code, expected sites of service, and payer coverage landscape. The publication also presents operational benchmarks relevant to laboratory billing for immunofluorescent parasitology testing, summaries of payer policy themes affecting coverage and prior authorization, and clinical context explaining when immunofluorescent testing for Giardia is typically used versus other diagnostic methods. Data limitations are noted where input fields are not provided. The piece is intended for laboratory managers, billing professionals, and policy analysts needing a focused reference on CPT code 87269 and its role in diagnostic workflows and payer interactions.
Billing Code Overview
CPT code 87269 describes a laboratory test in which a lab analyst performs an immunofluorescent assay to detect Giardia antigens. The service is a parasitology diagnostic test that uses immunofluorescence techniques to identify presence of Giardia organisms in clinical specimens.
Service Type: Laboratory / Diagnostic Test
Typical Site of Service: Clinical laboratory or hospital laboratory
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric patient presenting to an outpatient clinic, urgent care, emergency department, or hospital with acute gastroenteritis — symptoms include watery diarrhea, abdominal cramping, nausea, vomiting, and occasionally low-grade fever and weight loss. The clinician collects a stool specimen or orders a stool antigen test when Giardia lamblia (Giardia intestinalis) infection is suspected based on recent travel history, daycare exposure, contaminated water exposure, or persistent steatorrhea. The specimen is sent to the clinical laboratory. A medical laboratory scientist or technologist performs an immunofluorescent assay to detect Giardia antigens in the stool; the test involves reagent incubation, microscopic fluorescent reading, and documentation of results. Results are reported to the ordering provider for treatment decisions, such as initiation of antiprotozoal therapy or public health precautions. Typical sites of service include outpatient laboratories, hospital clinical laboratories, emergency departments, urgent care centers, and reference laboratories.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Normal, standard service | When the immunofluorescent Giardia antigen test is performed under typical circumstances without unusual procedural issues |
22 | Increased procedural services | When additional, documented technical effort beyond the usual is required (extensive troubleshooting, prolonged processing) |
26 | Professional component | When reporting only the professional component (interpretation/reading) separate from the technical component |
59 | Distinct procedural service | When this test is performed in a separate encounter or is distinct from other laboratory procedures on the same date |
62 | Two surgeons — co-surgery (included for completeness in lab billing contexts where multiple providers share professional responsibilities) | Rarely used for lab tests; used when two qualified providers share the professional component |
78 | Unplanned return to the operating/procedure room by the same physician following initial procedure (included for facility contexts where specimen collection required return) | Use only when clinically appropriate in facility settings requiring re-entry to collect or repeat specimen |
90 | Reference (outside) laboratory | When the specimen is sent to an outside/reference laboratory for testing |
TC | Technical component | When billing only the technical component (laboratory processing, reagents, equipment) |
QX | Ordering/servicing physician modifier for Medicare regulatory purposes (modifier for advanced practitioner/beneficiary relationships) | When the test is ordered and performed according to applicable supervisory/ordering rules (used with applicable practitioner combinations) |
52 | Reduced services | When the test is partially performed or limited in scope compared with the full procedure |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 261QM0800X | Clinical Pathology | Medical laboratory directors and pathologists overseeing immunofluorescent testing |
| 207RH0000X | Infectious Disease | Clinicians ordering testing for suspected parasitic infections |
| 207Q00000X | Emergency Medicine | ED physicians ordering stool testing for acute gastroenteritis |
| 363L00000X | Clinical Laboratory | Medical laboratory scientists/technologists performing the assay |
| 208000000X | Family Medicine | Primary care providers who commonly evaluate and order testing for diarrheal illness |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
A07.1 | Giardiasis | Direct diagnostic indication for Giardia antigen testing |
A09 | Infectious gastroenteritis and colitis, unspecified | Common presenting diagnosis when stool testing, including Giardia antigen, is ordered |
K52.9 | Noninfective gastroenteritis and colitis, unspecified | Considered when diarrhea persists and infectious causes need exclusion; antigen testing helps rule in/out Giardia |
R19.7 | Diarrhea, unspecified | Symptom-driven test ordering; used when diarrhea prompts stool pathogen testing |
K59.1 | Functional diarrhea | Used when chronic diarrhea is evaluated; Giardia testing performed as part of differential diagnosis |
B96.89 | Other specified bacterial agents as the cause of diseases classified elsewhere | May be used in combination when multiple infectious agents are identified; supports comprehensive stool testing |
Z11.3 | Encounter for screening for infections with a predominantly fecal-oral route of transmission | Used for screening in high-risk exposures (e.g., outbreak investigations) |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
87270 | Infectious agent antigen detection by immunofluorescent technique, all direct smears; additional organisms (each) | Used when multiple pathogens are evaluated by immunofluorescence on the same specimen in addition to Giardia |
87449 | Infectious agent antigen detection by enzyme immunoassay technique, multiple-step method, multiple organisms; each organism | Alternative stool antigen testing methodology (EIA) for Giardia or other enteric pathogens |
87447 | Infectious agent antigen detection by immunoassay technique; Giardia lamblia | Alternate CPT code commonly used for Giardia antigen testing when using immunoassay rather than immunofluorescence |
87045 | Culture, bacterial, stool, presumptive | Performed when bacterial enteropathogens are suspected concurrently with parasitic testing |
89250 | Breeding, screening or identification of parasites; microscopic stool exam for ova and parasites (O&P) | Traditional ova and parasite microscopic exam performed alongside antigen testing for comprehensive evaluation |
G0471 | Infectious agent detection by nucleic acid (DNA or RNA); enteric pathogen(s), multiple (e.g., gastrointestinal pathogen panel) | Molecular multiplex panels that may be ordered in lieu of or in addition to antigen testing for broader pathogen detection |